Goldman Sachs’s Tonix Pharmaceuticals TNXP Stock Holding History
Bought
Maintained
Sold
Other funds holding TNXP
JHC
Goldman Sachs's TNXP Position: Q3 2026 in Review
Goldman Sachs increased its Tonix Pharmaceuticals (TNXP) stake by 6.2% in Q3 2026, buying an estimated $72.4K and bringing the position to 104,487 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #5227.
Goldman Sachs first reported a position in TNXP in Q3 2021 and has held it in 10 quarters since. The position peaked at $1.26M in Q2 2026. 113 funds tracked by Wall St. Rank hold TNXP as of Q3 2026.
- Goldman Sachs held 104,487 shares of Tonix Pharmaceuticals worth $1.02M as of Q3 2026.
- Goldman Sachs bought 6,131 Tonix Pharmaceuticals shares in Q3 2026, an estimated $72.4K.
- Tonix Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #5227 holding.
- Goldman Sachs first reported a position in Tonix Pharmaceuticals in Q3 2021 and has held it in 10 quarters since.
- Goldman Sachs's Tonix Pharmaceuticals position peaked at $1.26M in Q2 2026.
- 113 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2026.
Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.